Bertha C M, Mattson M V, Flippen-Anderson J L, Rothman R B, Xu H, Cha X Y, Becketts K, Rice K C
Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
J Med Chem. 1994 Sep 16;37(19):3163-70. doi: 10.1021/jm00045a022.
The (E)-8-benzylidene and (E)-8-(3,4-dichlorobenzylidene), 7-ketone derivatives, 5 and 6, of the synthetic opiate 2-methyl-5-(3-hydroxyphenyl)morphan [5-(3-hydroxyphenyl)-2-methyl-2-azabicyclo[3.3.1]nonane, 1], were synthesized from the 7-ketone derivatives 2 or 4 via the Claisen-Schmidt reaction. The corresponding enantiomers of 5 and 6 were obtained in > 99% optical purity from the optical isomers of 4, resolved with the O,O'-dibenzoyltartaric acids. The absolute configurations of the enantiomers of 4 were determined by conversion, via Clemmensen reduction, to the enantiomers of 1, the configurations of which are known. The determination of the regioisomer and configurational isomer of 5, with respect to the introduced benzylidene group, was determined from a single-crystal X-ray analysis. 1H NMR data was used to confirm that 6 possessed the same configuration as 5. Radioreceptor binding studies in rat and guinea pig brain preparations revealed that (-)-(1S,5S)-5 displayed an 11-fold decrease in affinity for the opioid mu receptor and an increase in affinity for sigma receptors of 81-fold (low nanomolar affinity) relative to the ketone precursor (+)-(1S,5S)-4. An analogous, albeit less dramatic, trend was seen with compound (-)-(1S,5S)-6. Compounds (-)-(1S,5S)-5 and (-)-(1S,5S)-6 are distinct from the typical sigma-opiates in that they have very low affinity for either PCP sites or muscarinic receptors. The high affinity and selectivity of these novel sigma receptor ligands suggests that they will be valuable for the elucidation of the functional roles of sigma receptors.
合成阿片类药物2-甲基-5-(3-羟基苯基)吗啡烷[5-(3-羟基苯基)-2-甲基-2-氮杂双环[3.3.1]壬烷,1]的(E)-8-亚苄基和(E)-8-(3,4-二氯亚苄基)7-酮衍生物5和6,是由7-酮衍生物2或4通过克莱森-施密特反应合成的。5和6的相应对映体由4的光学异构体通过用O,O'-二苯甲酰酒石酸拆分获得,光学纯度>99%。4的对映体的绝对构型通过克莱门森还原转化为1的对映体来确定,1的构型是已知的。5相对于引入的亚苄基的区域异构体和构型异构体通过单晶X射线分析确定。1H NMR数据用于确认6与5具有相同的构型。在大鼠和豚鼠脑制剂中的放射受体结合研究表明,相对于酮前体(+)-(1S,5S)-4,(-)-(1S,5S)-5对阿片μ受体的亲和力降低了11倍,对σ受体的亲和力增加了81倍(低纳摩尔亲和力)。化合物(-)-(1S,5S)-6也观察到类似的趋势,尽管不太明显。化合物(-)-(1S,5S)-5和(-)-(1S,5S)-6与典型的σ阿片类药物不同,因为它们对PCP位点或毒蕈碱受体的亲和力非常低。这些新型σ受体配体的高亲和力和选择性表明它们对于阐明σ受体的功能作用将是有价值的。